Conflict of Interest
The European VALHUDES is a researcher-induced study, coordinated by
University of Milano-Bicocca (Monza, Italy), Sciensano (Bruxelles,
Belgium), Istituto Europeo di Oncologia (Milan, Italy), University of
Sassari (Sassari, Italy), U.O. Coordinamento Consultori Familiari, ASSL
Sassari – ATS Sardegna (Sassari, Italy), NHS Lothian, University of
Edinburgh (Edinburgh, Scotland), Trinity College Dublin (Dublin,
Ireland).
Manufacturers of HPV assays (GeneFirst, Oxford, UK and Hiantis, Milan,
Italy) and devices (Copan Italia Spa, Brescia, Italy and Novosanis,
Belgium) participated in the European VALHUDES framework contributing
equipment for laboratory testing under the condition of accepting
independent publication of results. The study group received free
self-sample collection devices from Copan Italia Spa (Brescia, Italy)
and Novosanis (Belgium) and free OncoPredict HPV assay from (Hiantis,
Milan, Italy).
CEC declares to have received research support from BD Diagnostics,
Seegene, Arrows Diagnostics, Copan, GeneFirst, Hiantis and VITRO. CEC is
a minority shareholder of Hiantis. ADI, AFP, FB, FO, GT, HE, KC, MM, CG,
RP declare no conflict of interest.